2 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Colorectal Tumor: new trials by email Literature Review of Colorectal Tumor trials Research Report on Colorectal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer enzastaurin, irinotecan, cetuximab - Colorectal Cancer, Colorectal Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 26 | 2007-03-01 | 2020-07-21 |
| Safety Study of 90Y-hMN14 to Treat Colorectal Cancer hMN14 (labetuzumab) - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Gilead Sciences | 72 | 2000-01-01 | 2021-08-19 |
Colorectal Neoplasms (3) · Colonic Neoplasms (2) · Rectal Neoplasms (1)
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3)
Cetuximab (2) · IFL protocol (1) · Irinotecan (1) · encorafenib (1) · enzastaurin (1) · labetuzumab (1)
Eli Lilly and Company (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gilead Sciences (1)
United States (2) · Germany (1) · Hungary (1) · Italy (1) · Sweden (1) · Switzerland (1)
Maria Alessandra Calegari (1) · William Wegener, MD (1)
2023 (1)